According to the TCGA, the percentage of tumors with putative ERBB4 driver mutations are highest in melanoma and esophagogastric, followed by endometrial cancer, colorectal cancer, and NSCLC (Figure 5A). The gene discussed is ERBB4; the disease is endometrial cancer.